Clinical Trials Logo

Clinical Trial Summary

Primary objective:

To evaluate the impact of 12 weeks' administration of extended release niacin/laropiprant (ERN/LRPT) compared to placebo added to statin therapy on endothelial dependant dilatation of the arterial wall assessed by brachial vasoreactivity in stable coronary heart disease (CHD) patients.

Secondary objective:

To evaluate the impact of 12 weeks' administration of extended release niacin/laropiprant (ERN/LRPT) compared to placebo added to statin therapy on serum lipids and the parameters of inflammation in stable coronary heart disease (CHD) patients.

CHD-coronary heart disease ER-extended release


Clinical Trial Description

Endothelial dysfunction can be regarded as a syndrome which exhibits systemic manifestations and is detectable prior to obvious intimal lesions which are considered to be important factors in the pathogenesis of atherosclerosis and its complications. Endothelial function is determined by the integrated index of all atherogenic and atheroprotective factors present in an individual, including known, as well as yet unknown variables and genetic predispositions. Should the hypothesis of endothelial dysfunction reflecting a vascular phenotype prone to atherogenesis be true, endothelial function could then serve as a marker of an inherent atherosclerotic risk. Dysfunction of either the coronary or peripheral vascular endothelium can be considered an independent predictor of cardiovascular events, offering valuable prognostic information additional to that derived from conventional risk factor assessment. Interventions, such as risk factor modification and treatment with various drugs, including statins and angiotensin-converting enzyme inhibitors, have shown to improve endothelial function.

Endothelial dependant vasomotion has been used as a clinical endpoint for assessment of endothelial function. Testing involves pharmacological and/or physiological stimulation of endothelial release of NO and other vasoactive compounds, and often a comparison of vascular responses to endothelium-independent dilators such as nitroglycerine. Determination of local NO bioavailability not only reflects its influence on vascular tone, but also the other important functions of this molecule, which include thromboregulation, cell adhesion, and proliferation

A non-invasive technique has been developed to evaluate endothelium-dependent, brachial artery FMD. Endothelium of the brachial artery is provoked to release nitric oxide (NO) by the pressure created by inflated sphygmomanometer cuff placed on the forearm distal to the brachial artery and its subsequent release 4-5 minutes later.FMD occurs predominantly as a result of local endothelial release of NO and it can be imaged and quantitated as an index of vasomotor function. The advantages of this high-frequency ultrasonographic imaging of the brachial artery are two-fold: it is non-invasive and it allows repeated measurements.

Large prospective epidemiological studies have demonstrated an inverse correlation of high density lipoprotein cholesterol (HDL-C) and the risk of cardiovascular events. Although the atheroprotective effects of HDL have mainly been attributed to its function in reverse cholesterol transport, lately numerous beneficial effects of HDL such as the improvement of endothelial function, anti-inflammatory, anti-thrombotic, antioxidative effects and the stimulation of endothelial regeneration have been identified. Consequently, therapeutic elevation of HDL become more and more important goal of the treatment of patients with coronary artery disease (CAD). Warnholtz et al recently demonstrated that extended-release (ER) niacin 1000 mg daily significantly improved endothelial function in CAD patients with low HDL-C, but not in normal HDL-C. The biggest obstacle for niacin therapy is flushing which makes many patients non compliant to the prescribed medication.

Tredaptive TM [(ERN/LRPT); Merck & Co., Inc, Whitehouse Station, NJ, USA)] is a combination tablet containing 1 g of extended release niacin (ERN) and 20 mg of laropiprant, highly selective PGD2-receptor (DP1) antagonist, which offers improved tolerability, supporting a simplified 1-2 g dosing paradigm and improved compliance.

Statins and niacin have been shown to improve endothelial function in CAD patients, however, the question whether niacin improves endothelial function in statin treated patients still remains open. What would be the time needed to show an effect is also not known, but based on the recent publication by Warholtz it seems that 12 weeks should be sufficient.

This study would prospectively test influence of the higher dose of ER-niacin (2000mg) than used in the latest publications (1000 mg) in addition to laropiprant (40mg) in the CHD patients with low HDL-C, the subgroup which in the recent publication by Warhnoltz seem to have benefited from the treatment with niacin. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01126073
Study type Interventional
Source University Medical Centre Ljubljana
Contact
Status Completed
Phase Phase 4
Start date September 2010
Completion date October 2011

See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Completed NCT05088291 - Application of a New X-ray Protective Device in Coronary Interventional Therapy
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Not yet recruiting NCT04995159 - Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System N/A
Recruiting NCT02967718 - Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome N/A
Completed NCT02888652 - Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
Terminated NCT02045134 - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery N/A
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Completed NCT02753829 - Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease N/A
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Completed NCT01920009 - Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Recruiting NCT01689688 - Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography N/A
Completed NCT01779401 - Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients N/A
Recruiting NCT01462799 - COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care N/A
Recruiting NCT01456364 - Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Phase 4
Completed NCT01428947 - Does Coronary Angiography Cause Cognitive Dysfunction? N/A